Written and maintained by CASRAI Editorial Board
Last updated
A massive transfusion protocol (MTP) is a hospital’s predefined, pre-authorized process for rapidly supplying large volumes of blood products, in fixed ratios, to a patient with life-threatening hemorrhage. The purpose of having a protocol rather than relying on individual product orders is speed: in uncontrolled hemorrhage, waiting for sequential order-and-release cycles for red cells, plasma, and platelets costs time the patient does not have. An MTP pre-authorizes the transfusion service to release standardized “packs” or coolers of product on a single activation call, and adjusts or stands the protocol down as the clinical picture changes.
This guide is a companion to Hemovigilance: What It Means and How CDC NHSN Reporting Works, which covers surveillance and adverse-event reporting for transfusion generally; MTP is the acute clinical protocol that sits upstream of the transfusions being monitored.
What counts as “massive” transfusion
There is no single universal numeric definition, but commonly used thresholds for classifying a transfusion episode as massive include: replacement of one estimated total blood volume within 24 hours; replacement of 50% of blood volume within 3 hours; transfusion of 10 or more red blood cell (RBC) units within 24 hours; or a rate of 4 or more RBC units in one hour with anticipated ongoing need. These thresholds are typically used retrospectively to classify an episode for audit and research purposes. Clinically, MTP is activated prospectively, before those thresholds are necessarily met, based on evidence of ongoing uncontrolled hemorrhage and a clinical judgment that massive transfusion is likely to be needed.
Activation criteria
Because waiting for lab-confirmed thresholds defeats the purpose of a rapid-release protocol, activation is usually triggered clinically rather than by a lab value. Common triggers used across trauma, obstetric hemorrhage, and GI bleed protocols include:
- Clinical judgment of ongoing, uncontrolled hemorrhage with hemodynamic instability
- A calculated risk score, such as the Assessment of Blood Consumption (ABC) score or shock index (heart rate divided by systolic blood pressure), used particularly in trauma to flag patients likely to need massive transfusion before formal thresholds are reached
- Ongoing transfusion requirement despite initial resuscitation (e.g., persistent hypotension after initial RBC units)
- Obstetric hemorrhage exceeding expected blood loss with continued bleeding (many hospitals run a dedicated obstetric hemorrhage/MTP variant given the different baseline physiology of pregnancy)
Activation is typically a single phone call or a dedicated order set/paging alert to the blood bank, which then begins releasing pre-composed product coolers without requiring individual product orders for each unit.
Product ratios
Most modern MTPs release red cells, plasma, and platelets in a fixed, balanced ratio rather than red cells alone, reflecting evidence (including the PROPPR trial, a multicenter randomized trial published in JAMA in 2015) that a balanced approach more closely mimics whole blood and reduces early mortality from hemorrhage compared with RBC-heavy resuscitation. A commonly used starting ratio is approximately 1:1:1 (RBC:plasma:platelets), with cryoprecipitate added for fibrinogen replacement, though exact institutional ratios and triggers for cryoprecipitate vary. Increasingly, institutions incorporate viscoelastic testing (thromboelastography/TEG or rotational thromboelastometry/ROTEM) once available, to move from a fixed empiric ratio toward goal-directed component replacement as the episode progresses.
Cooler composition and logistics
To achieve rapid delivery, transfusion services typically pre-pack MTP coolers containing a fixed number of RBC and plasma units (and platelets, where feasible to include) so the first cooler can leave the blood bank immediately on activation, often using uncrossmatched group O RBCs (O-negative for patients of childbearing potential where blood type is unknown, transitioning to type-specific or crossmatched units as a type and screen result becomes available). Subsequent coolers follow on a defined interval or on request as the clinical team works through the initial supply, with the transfusion service tracking cumulative units issued against the ratio target.
The laboratory’s role
The blood bank/transfusion service carries several specific responsibilities once MTP is activated:
- Immediate release of uncrossmatched or partially crossmatched RBCs, per the institution’s emergency-release policy, rather than waiting for a full compatibility workup
- Pre-thawing plasma ahead of anticipated need (thawed plasma has a defined shelf life once thawed, which drives inventory planning for MTP-ready stock)
- Tracking utilization against the ratio target and communicating running totals to the clinical team
- Managing type and screen/crossmatch workflow in parallel, converting to type-specific and fully crossmatched units as soon as results allow, to conserve O-negative inventory for other patients
- Coordinating stand-down when the clinical team declares hemorrhage control, including managing any unused, unopened product return per institutional policy
- Post-event review of MTP activations, feeding into the hospital’s hemovigilance and transfusion committee review process
Frequently asked questions
Who can activate an MTP?
This is institution-specific, defined in the hospital’s MTP policy — commonly any attending or senior resident/registrar in the treating service (trauma, emergency medicine, obstetrics, surgery) can activate without requiring blood bank physician sign-off first, given the time-critical nature of the decision.
How is MTP different from a routine transfusion order?
A routine transfusion is ordered and released unit by unit, typically after a completed crossmatch. MTP pre-authorizes release of multiple units in a fixed ratio on a single activation, using emergency-release (uncrossmatched) product where necessary, specifically to remove the sequential ordering delay.
Does every hospital use the same product ratio?
No. Institutions set their own MTP policy, informed by the balanced-ratio evidence base, but exact ratios, cooler contents, and cryoprecipitate/fibrinogen triggers vary by hospital and patient population (trauma vs. obstetric vs. GI bleed protocols often differ).
See also: Hemovigilance: What It Means and How CDC NHSN Reporting Works.
